Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611936 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL28223088 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL614707 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL28222365 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL614494 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL615431 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL614039 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL614861 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL10712750 | 0.97 | SIGMAR1 (0.50) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 | |
| SCHEMBL5948987 | 0.95 | SIGMAR1 (0.47) | SIGMAR1PLA2G1BPLA2G2ALMNACACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210230538-A1 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-07-29 | — | — | US | disclosed |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10544100-B2 | Autophagy inhibitors | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2265617-A1 | SOLVENTS | Bioniqs Limited (GB) | 2010-12-29 | — | — | EP | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009034329-A1 | SOLVENTS | BIONIQS LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-7101940-B2 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-09-05 | — | — | US | disclosed |
| US-7034173-B2 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-04-25 | — | — | US | disclosed |
| US-6953829-B2 | Catalyst system and the use thereof | BASELL POLYOLEFINE GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20030144434-A1 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | EQUISTAR CHEMICALS, LP | 2003-07-31 | — | — | US | disclosed |
| US-20030013913-A1 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | EQUISTAR CHEMICALS, LP | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544100-B2 | Autophagy inhibitors | BECN1, ATG7, SQSTM1 | SIGMAR1 2365/4885PLA2G1B 3823/4885PLA2G2A 3430/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | SIGMAR1 3349/4885PLA2G1B 3670/4885PLA2G2A 3027/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | SIGMAR1 376/4885PLA2G1B 2023/4885PLA2G2A 1552/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | SIGMAR1 3349/4885PLA2G1B 3670/4885PLA2G2A 3027/4885 |
| US-20030144434-A1 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | CBR1, COX6C, CBR3 | SIGMAR1 657/4885PLA2G1B 1146/4885PLA2G2A 1543/4885 |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | SIGMAR1 4049/4885PLA2G1B 4676/4885PLA2G2A 4850/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | SIGMAR1 4733/4885PLA2G1B 4492/4885PLA2G2A 4249/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | SIGMAR1 4815/4885PLA2G1B 4215/4885PLA2G2A 3572/4885 |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | SIGMAR1 3463/4885PLA2G1B 1586/4885PLA2G2A 1326/4885 |
| US-20030013913-A1 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | SCO2, CNOT1, CYC1 | SIGMAR1 1577/4885PLA2G1B 3427/4885PLA2G2A 4635/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | SIGMAR1 791/4885PLA2G1B 4135/4885PLA2G2A 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.